Halia Therapeutics, a biopharmaceutical company that completed a $30 million Series C financing last year, has announced key leadership additions and promotions.

Dr. Margit Janat-Amsbury, Chief Scientific Officer

Dr. Margit Janat-Amsbury, MD. PhD. has been promoted to Chief Scientific Officer.

In her new role, she will lead Halia’s scientific vision, guiding the discovery and development of innovative therapies that align with the company’s mission to improve patient outcomes. Her leadership has been instrumental in advancing the clinical success of Halia’s pipeline, including the development of its flagship programs targeting inflammation and metabolic disorders.

Other Appointments

Halia also welcomed Tracey Clayton as Vice President of Program Management & Clinical Operations and Stephen Anthony DO as Senior Vice President of Clinical Development. Both bring decades of expertise in clinical trial execution and operational excellence.

Clayton, formerly an Executive Director and Head of Program Management Oncology at Sumitomo Pharma America, Inc., has extensive experience in global clinical trial management.

Anthony, who previously served as Chief Medical Officer at Newave Pharmaceutical Inc., specializes in regulatory compliance and operational strategy. Together, these additions will play pivotal roles in advancing Halia’s robust clinical pipeline.

“Today marks a significant milestone in Halia’s journey,” said Dr. David J. Bearss, President & CEO of Halia Therapeutics. “These leadership changes ensure Halia is well-positioned to deliver on our mission of transforming lives through developing groundbreaking therapies targeting chronic inflammation for multiple diseases.”